What is Atea Pharmaceuticals, Inc. (AVIR)?

Atea Pharmaceuticals, Inc. (AVIR) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of AVIR?

The current price of AVIR is $4.17. Prices are updated in real time on Stocks360.

What is AVIR's price-to-earnings (PE) ratio?

AVIR's trailing twelve-month PE ratio is -2.00, based on current price and earnings per share data available on Stocks360.

What is AVIR's market capitalization?

AVIR's market capitalization is $334,453,595.00, placing it in the small-cap tier.

Atea Pharmaceuticals, Inc. (AVIR)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$4.17

Market Cap

$334.45M

PE (TTM)

-2.00

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.28

Day Range

$4.11 – $4.29

52-wk Range

$2.87 – $6.45

Avg Volume

N/A

Volume

245.24K

Atea Pharmaceuticals, Inc. (AVIR) is a publicly traded company in the Healthcare sector. Latest price: $4.17. Market cap $334.45M. Trailing PE -2.00. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-28 · $3.21 2026-10-27 · $4.17 (+29.91%)

Earnings

Most Recent

Aug 12, 2026

EPS $-0.41 vs est. $-0.56

Beat by $0.15

Next Earnings

Nov 11, 2026

EPS estimate $-0.51

Proprietary Signals

Signal snapshot temporarily unavailable.

About Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). The company also developing AT-587, that is in Phase 1 clinical trial for the treatment of chronic HEV infection. In addition, it offers a proprietary platform of nucleosides and nucleotides for virology, medicinal chemistry, and antiviral drug development. The company has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-2.00×
P/S (TTM)	0.00×
P/B	1.64×
PEG	0.08×
P/FCF (TTM)	-2.20×
EV / EBITDA	-1.51×
EV / Sales	0.00×
Earnings Yield	-49.52%
Free Cash Flow Yield	-45.47%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$258.33M
Net Income (TTM)	-$165.61M
Free Cash Flow (TTM)	-$152.07M
Net Debt	-$76.12M
Working Capital	$200.54M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-64.25%
Return on Invested Capital	-86.35%